We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Ultrasis | ULT | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.095 | 0.095 |
Top Posts |
---|
Posted at 07/4/2024 14:11 by humphries1 Yep we got them going, they knew a long time in advance what was going to do, we did have a warning and we didnt listen, one of the shareholders got in touch with the board, and the board said we hate private investors, THE WRITING WAS ON THE WALL at that point and we all still held |
Posted at 07/4/2024 12:42 by humphries1 I thought smith and bell were dead investors revolt bloody shame if the aint dead |
Posted at 04/3/2024 15:14 by woollworth Humph the 🐖 wake, sent invites to Katie Price, Chainlink, derwent 1 3 and 5, all the ultrasis investors, staff John Smith, Paul Bell and Gerry Malone, Nigel Brabbins all in the seychelles living off our dosh. |
Posted at 15/9/2023 12:25 by humphries1 Rollover wooly..Rolling over a contract, or rollover, means that investors and traders carry forward the futures position from the current month in which it is held to the next month. The rollover is conducted closer to the date of expiry of the current month's contract. Rollovers happen for reasons best known to individual investors. |
Posted at 25/8/2023 21:49 by woollworth OK but it hits the top line of a new business, typical SOH.Possibly why opti is going south at the mo. Think back soh boasted profit then employed numerous other staff which caused investors massive loss, staff first, PI's last... Name of the aim g aim, them first us last, expect more drops next week imo, be very surprised if not, I've been shouting about this for ages, we can now see why its dropping. |
Posted at 24/7/2023 12:13 by humphries1 Hi wooly this from ELRAMPO..Peeps,TBC, I was not suggesting SOH misled investors or me with his comments in 2018 - my point was one of perception from discussions with investors and comments on forums, etc. Of course, SOH will have been privy to much of what the potential partners were strategising regarding taste, storage testing, etc. The fact CC was sat of SweetBiotix for two years must have frustrated SOH no end. This is the price with Fledglings partnering with global corps; it is a risk that needs to be taken when ambitions are so great. There's not a lot you can do about it.Ref AQSEI spoke to SOH about AQSE just last week. He made an astonishing comment which I pushed back on. It concerned me because it suggested he does not see the problem as we investors do. I also explained that iWeb does not provide access via SIPP or ISA. II will provide access via their trading platform, but not in a SIPP.For example, I mentioned that I made added to my PBX in-specie position, but it showed a 39% loss due to a significant difference between BID and OFFER prices. I reminded him of my concern that this would be a problem and the most likely reason for the share price destruction. The SOH compared it to AIM suggesting there is not much difference in this regard. I explained that it was not similar - I pointed out that the spread of stocks in my AIM portfolio is usually about 5-10%, not the much larger 40-50%. |
Posted at 21/7/2023 06:50 by humphries1 OptiBiotix Health jumps on novel sugar substitute update?Lauren GibbonsVox Newswire11:38, 19th July 20230?OptiBiotix Health (OPTI) OPTI, a life sciences company specialising in microbiome-based health products, provided an overview of its SweetBiotix product range in response to growing market interest in sweeteners.The sugar substitutes market is projected to reach US$24.3bn by 2028, driven by demand for healthier, low-calorie options. However, widely used sugar substitutes have potentially negative health effects, including increased blood sugar levels, DNA damage, and possible carcinogenic effects. OptiBiotix addresses a clear market need for better alternatives with its SweetBiotix product portfolio, which includes patented, zero, or low-calorie sweet dietary fibers. SweetBiotix fibers have a prebiotic effect, promoting the production of short-chain fatty acids in the gut, offering additional health benefits.OptiBiotix has partnerships with industry leaders like Kellogg's, Nestle, Coca Cola. The company is scaling up its manufacturing process to meet the demands of these partnerships, securing manufacturing agreements with US and Firmenich. These partnerships endorse the science underpinning SweetBiotix, and its commercial potential. The company is in the final stages of manufacturing scale-up and testing for its products. It expects to receive test results over the summer, which will allow it to move forward with partner application development and launch plans. View from VoxOptiBiotix has demonstrated, through progress made in commercial-scale production and the positive feedback from partners, that the science and potential of its SweetBiotix product range are likely to position it as a key player in the sugar substitutes market. Investors have reacted positively to the news, pushing OptiBiotix shares up 51% at time of writing. ?OPTI.LOpti |
Posted at 25/1/2023 17:51 by woollworth Hmmm sounds good humph, as usual, but the employment of Steen Anderson will be very costly and his position requires another vehicle etc, what about expanding the business a pay investors a bit back, rather give it to new (high salary staff) and their vehicles etc.Quote experienced employees to in crease income and profitability and value for investors, NO! This is where it falls apart, we continually lose and will continue to do so because off staff and high overheads which include, office staff organise wages paye, answering telephones, mail etc, then they all need holiday pay and a contribution towards their pension fund, probably receive free shares. Every time SOH employs more staff it moves investors away from pay back... Not forgetting quote, return a profit 18 months ago, since then share price collapsed from over a quid. While this continues - we sink lower and lower, you could say lower.....lol |
Posted at 10/11/2022 13:26 by humphries1 OptiBiotix Health PLC Investor updateSource: RNS Non-RegulatoryTIDMOP |
Posted at 03/6/2022 13:05 by humphries1 DW, Some of the bears you fear to hear from have been around for many years, some from IPO. Constantly sniping at alternative views to yours is not helpful and weakens your position. Years of bullish language to which I have contributed have not been beneficial to a balanced, informative discussion.TT, thanks for hosting the Twitter Spaces talk yesterday. I missed the first 20 minutes, but it was clear you had a lengthy, detailed chat with SOH, MUCH of which could prove very useful for investors. Moreover, if delivery of new product launches and "progressive sales" becomes evident, perhaps we see a change in investor sentiment. LPLDL dairy products as well as the holy grail of sugar, SweetBiotix being tangible products, then OPTI, PBX will have far more investors, and those that have stuck by SOH will be vindicated and much happier.LPLDL dairy- [ ] LPLdl dairy launch a highly significant milestone, completely overlooked by marketElric: True, but this is likely due to the calibre of the SA partner. Speaking for myself (I suspect I am not alone), it will need news that Arla, Agropur and Fonterra were ready to launch a consumer-facing product(s) immediately. Right now, it is likely to be c12-months away at best?- [ ] 1st of its kind Probiotic with a Scientific backed claims for Cholesterol reduction in the $54bln p.a dairy marketElric: The potential here is quite significant. As I said yesterday during your Twitter chat, LP-LDL seems to be out on its own as a peer-reviewed probiotic with both GRAS and FDA accreditation, which should be a significant advantage. Can SOH take advantage of this? If so, how long will it take to get a commercial agreement over the line with T&C he is happy with? I know of two highly significant deals he could not bring home, details of which I cannot go into.- [ ] Significant technical challenges had to be overcome to get a novel Probiotic (I.e. LPLDL) in a dairy product without compromising taste, shelf life etc.- [ ] LPLDL can now scale more rapidly in dairy (6-12 months with new partners products rather than 2.5 years)Elric: Communicating these issues to investors has been problematic, so I interviewed Per, and other heads of departments because I felt investors needed to know about the technical hurdles and facilities required. This was an effort to prepare for the longevity of these projects. We are used to pharma-related products' longevity but less so with OTC, and dairy, baked, and beverage goods. These have taken longer than anticipated, myself included.PBX - General- [ ] IIâs have been contacting SoH to enquire about Stock availability- letâs see what developsElric: Where will the II stock come from?PBX AQUIS LISTING- Decision was taken to list on AQSE over AIM due to lower risk and costElric: As I said yesterday. I think SOH has tried to be frugal again and will look to list on AIM ahead of the lock-in period expiration. IMHO this is a must; not doing so would likely result in a PBX bloodbath as investors seek to cash in. POLB is an example of investor impatience and an unwillingness to be locked in. Many exited. A more liquid market would be required if the same were to occur with PBX.SWEETBIOTIX- [ ] Industrial scale Sweetbiotix optimisation now completed (this was a complex challenge with many technical issues to overcome)- [ ] We now have industrial scale high purity Sweetbiotix product which has been provided to partners for their functionally testing- [ ] Lots of interest and progress with Sweetbiotix partners, could have had a deal end of last year but terms not quite right for OPTI - Anticipate more corporate news soonElric: Potential game-changer, but this garden path has proved exceptionally long and perhaps a little overgrown! Overcoming technical difficulties has not been communicated early enough. August 2018, with an in-depth chat with me, proved costly because the "top-slicing now it, not the right time" SOH citing corporate activity and "competitive tension" suggesting a global partnership deal could land anytime.- [ ] Emphasise on getting the right deal - wonât be giving away Sweetbiotix on the cheap (Golden goose!) - remains very confident (right) deal will be doneElric: IMHO, 3DM has seriously inhibited SOH, and fear of a repeat may play a negative role.- [ ] Sweetbiotix not used for Go-figure at present, this helps with bargaining position (Corps want exclusivity)Elric: Tosh! If SOH genuinely believed this, there would be no online store containing own-brand products. A truly global partner would not be concerned with the UK focused online store. This excuse has never made sense because it directly contradicts existing partners for SlimBiome and LPLDL.- [ ] JV partner deal will likely see Sweetbiotix in Go-FigureSHARE PRICE- [ ] Awful market, even good news having little or no impact- [ ] SoHâs attention will be to focus on building the business and creating value by delivering newsflow. He feels trying to market OPTI in the current market is futile.Elric: This talk will not sit well with investors. It is a poor analysis of the historical facts. We have been in a bull market for years, yet OPTI has constantly drifted. The constant use of SBTX as the ATM has told investors that OPTI is not yet efficient enough to stand on its own through sales growth and cash invoices. Moreover, new product launches have been delayed, and many partners have still not launched, and those that have are no longer available. Plus, the online presence of some LPLDL products is not as prominent as they once were. And, of course, investors I speak to now want some form of a statement from SOH that OPTI is not being screwed on margins to hold off passing increased costs to the consumer. SOH ignored this very concern when I put it to him.OTHER- [ ] APOLLO and Nandi launches are progressing - a little slower than hoped - but should launch in next month or two (not in our control of course) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions